Israeli man facing early-onset Alzheimer's develops potential treatment for Parkinson's disease

Ofer Shina, a 38-year-old Israeli product manager with no biology background, founded X-tosis after learning he carries a gene for early-onset Alzheimer's. The startup, based on Prof. Varda Shoshan-Barmatz's VDAC1 research, received a $2.74 million grant from the Michael J. Fox Foundation to develop a treatment for Parkinson's disease, with future plans to address Alzheimer's.

Ofer Shina, a 38-year-old Israeli product manager with no biology training, founded the biotech startup X-tosis after discovering he carries a gene mutation (PSEN1) that causes early-onset Alzheimer's. The company is built on research by Prof. Varda Shoshan-Barmatz at Ben-Gurion University of the Negev, who has studied the VDAC1 protein for 25 years. VDAC1 acts as a gate in mitochondria; under stress, excess protein forms pores that release molecules triggering cell death and inflammation. Shoshan-Barmatz's drug candidate VBIT-4 (renamed XTS001) blocks these pores. The Michael J. Fox Foundation awarded X-tosis a $2.74 million grant in June 2026 to move the drug toward human trials for Parkinson's disease, with plans to later target Alzheimer's. Shina initially faced rejection from both the scientist and the university's tech transfer arm, BGN Technologies, but persisted for a year. The company is based in Gainesville, Florida, because Shina determined that Israeli investors were unlikely to fund the long development timeline. The article notes that the war following October 7, 2023, hindered Israeli scientists' ability to travel to investor conferences.

Israeli man facing early-onset Alzheimer's develops potential treatment for Parkinson's disease